Table 1.
Descriptive table of sample characteristics.
Data are presented as median (IQR) for continuous measures, while for categorical variables count (percentage) are provided. The percentage relative frequencies for the variables “Major types of seizures” and “Types of seizures” are calculated considering the total number of subjects with a history of seizures.
| Sample Characteristics | n = 272 |
|---|---|
| Sex: Male | 167 (61.4%) |
| Age (years) | 63 (55–71) |
| Tumor site | |
| Pre-central | 110 (40.8%) |
| Post-central | 56 (20.6%) |
| Temporo-insular | 94 (34.6%) |
| Basal ganglia/midbrain/multicentric | 12 (4.0%) |
| History of seizures: Yes | 88 (32.4%) |
| Major types of seizures | |
| Focal | 38 (43.2%) |
| Generalized | 43 (48.9%) |
| Secondary generalization | 7 (8.0%) |
| Types of seizures | |
| Aphasic seizures | 6 (6.8%) |
| Absences | 2 (2.3%) |
| Motor seizures | 60 (68.2%) |
| Neurovegetative seizures | 2 (2.3%) |
| Sensitive seizures | 4 (4.5%) |
| Visually sensitive seizures | 5 (5.7%) |
| Uncinate seizures | 9 (10.2%) |
| MGMT promoter methylation: Yes | 101 (37.1%) |
| Type of surgery | |
| Supramaximal resection | 17 (6.6%) |
| Gross total resection | 196 (76.0%) |
| Subtotal resection | 30 (11.6%) |
| Biopsy | 15 (5.8%) |
| Adjuvant radiotherapy: Yes | 186 (68.6%) |
| Adjuvant temozolomide: Yes | 199 (73.4%) |
| Use of Levetiracetam/Lacosamide | |
| Levetiracetam | 99 (36.4%) |
| Lacosamide | 31 (11.4%) |
| Both of them | 35 (12.9%) |
| Neither of them | 107 (39.3%) |
| Seizures after surgery | |
| None | 170 (62.5%) |
| One | 65 (23.9%) |
| Two or more | 37 (13.6%) |